A committee of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend Moderna's new mRNA influenza vaccine for adults aged 50 and older. All nine members of the committee participated in the vote.
✓ AI-Debiased Article
5
Wire-neutral
L
R
No clear lean
✓ verified
Why this rating? · 1 signal
Signals flagged in the original
- framing: headline asserting a conclusion
Analyzed by our bias model Full breakdown ↓
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over
The FDA committee has unanimously recommended Moderna's mRNA influenza vaccine for adults aged 50 and over. This marks the first vaccine recommendation by the committee since 2023.
Companies
Moderna
Annotating as
No note attached
on this article.
Read next
FDA Advisory Panel Recommends Approval of Moderna's mRNA Flu Vaccine for Older Adults
The Hill
FDA Advisors Support Approval of Moderna's mRNA Flu Vaccine
Ars Technica
FDA panel reviews Moderna's mRNA flu vaccine for older Americans
PBS NewsHour
FDA Panel Reviews Moderna's mRNA Flu Vaccine for Older Adults
Guardian — US
Bias Analysis
Bias score
5/100
wirepublicmainstream
flavoredpartisanadvocacy
Inflammatory language
0/100
Sentiment
+10/100
Bias Indicators Removed
- ✕ framing: headline asserting a conclusion
Original vs. Neutral
Original Headline
Key FDA committee unanimously recommends its first vaccine since 2023
Neutral Headline
FDA Committee Recommends Moderna's mRNA Influenza Vaccine for Adults 50 and Over